ANRO Company Profile and Key Details

NYSE : ANRO

Alto Neuroscience

$15.22

1.11+7.87%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Alto Neuroscience, Inc. (ANRO) stock surged +7.87%, trading at $15.22 on NYSE, up from the previous close of $14.11. The stock opened at $14.35, fluctuating between $14.27 and $15.40 in the recent session.

Stock Snapshot

14.11

Prev. Close

472.83M

Market Cap

14.265

Day Low

-7.15

P/E Ratio

-2.13

EPS (TTM)

N/A

Cash Flow per Share

14.35

Open

31.07M

Number of Shares

15.4

Day High

79.39%

Free Float in %

N/A

Book Value

274.28K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 06, 2026	14.35	15.41	13.91	15.22	299.44K
Feb 05, 2026	14.68	15.34	14.02	14.11	312.63K
Feb 04, 2026	16.00	16.06	14.58	15.00	334.09K
Feb 03, 2026	16.05	16.30	15.83	16.16	150.62K
Feb 02, 2026	15.28	16.25	14.40	15.81	245.02K
Jan 30, 2026	15.34	15.61	14.38	15.48	199.31K
Jan 29, 2026	15.25	15.50	14.75	15.32	311.9K
Jan 28, 2026	16.76	16.76	15.30	15.33	116.64K
Jan 27, 2026	16.41	17.00	16.41	16.81	69.62K
Jan 26, 2026	16.34	17.07	16.05	16.41	189.8K
Jan 23, 2026	17.00	17.39	16.57	16.61	135.23K
Jan 22, 2026	17.62	18.09	17.18	17.18	110.69K
Jan 21, 2026	17.60	17.94	16.94	17.59	98.34K
Jan 20, 2026	16.67	18.50	16.30	17.42	202.02K
Jan 16, 2026	17.07	17.51	16.55	17.17	206.77K
Jan 15, 2026	17.13	17.14	16.60	17.02	84.35K
Jan 14, 2026	16.57	17.50	16.08	17.16	148.24K
Jan 13, 2026	17.34	17.34	15.90	16.50	147.62K
Jan 12, 2026	16.33	17.02	15.68	16.94	135.45K
Jan 09, 2026	16.05	17.47	15.69	16.37	214.23K

Contact Details

Mountain View, CA 94022

United States

https://www.altoneuroscience.com 650 200 0412

About Company

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

Stock Peers

AMAM

0.02+0.07%

Ambrx Biopharma Inc.$28.00 PTHS

-0.331-1.42%

Pelthos Therapeutics Inc.$22.99 RCUS

1+4.99%

Arcus Biosciences, Inc.$21.03 EVMN

0.65+3.90%

Evommune, Inc.$17.31 BHVN

0.84+7.81%

Biohaven Ltd.$11.60 DNA

1.78+21.39%

Ginkgo Bioworks Holdings, Inc.$10.10 BTX

0.27+4.30%

BlackRock Technology and Private Equity Term Trust$6.55 NUVB

0.08+1.42%

Nuvation Bio Inc.$5.70 ADCT

0.1+2.56%

ADC Therapeutics S.A.$4.01 ANVS

0.05+2.05%

Annovis Bio, Inc.$2.49

Company Overview

Alto Neuroscience, Inc. (NYSE:ANRO) closed at $15.22 USD, gaining $1.11 (7.87%) from the previous close of $14.11. The stock is currently mid-range between its 52-week high and low $1.60 and $20.91. With a market capitalization of about $472.83 million, Alto Neuroscience, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.85). Key stats such as the average daily volume over the past year has been around 322.84 thousand shares, in line with its 52-week average. Headquartered in Mountain View, CA, Alto Neuroscience, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Amit Etkin, the company employs approximately 76 people and listed since February 02, 2024. Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -6.51%, SMA50 -5.78%, SMA200 97.72%). The stock’s 14-day RSI is 44.6 (neutral), while the ATR of 1.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -27.2% below its high and over 851.25% above its low. Average 10-day trading volume of 226.59 thousand shares is below the 3-month average of 312.32 thousand, indicating normal recent market interest.

Valuation Metrics

Alto Neuroscience, Inc. trades at a P/E ratio of -6.63, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.7 trading at moderately above to book value. The P/FCF stands at -8.79, also below market averages.

Dividend & Fair Value

Alto Neuroscience, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.15. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of -1.62% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $10.00. The high target offers 228.52% upside. The low target suggests -34.3% downside. The mean target is $21.50. This offers 41.26% upside. Alto Neuroscience, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -21.21%. The prior quarter beat by 14.04%. Over the last six quarters, Apple has recorded several small beats. These include -15.49% in August 13, 2024.

Shareholding & Insider Activity

Alto Neuroscience, Inc. has 31.07 million shares outstanding. The public float is 20.75 million shares, elevated short interest at 8.58% of float. This equals 2.17 million shares. The short ratio is 5.51 days. Institutional investors hold 70.51% of the float. Insiders own 6.52%.

Financial & Profitability Overview

Over the trailing twelve months, Alto Neuroscience has not generated any revenue.
On valuation metrics, Alto Neuroscience trades at a P/E of -6.63, P/S of 0.00 and P/B of 3.70. The current ratio is 15.42 and quick ratio is 15.42. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1731.65 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.25, supported by a cash flow-to-debt ratio of -1.94.

Price Forecast & Outlook

Our AI price prediction model suggests that Alto Neuroscience, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.48%, with price expected at $13.93 by February 20, 2026, within a range of $12.81 to $15.13 3-Month Outlook: Projected rise of 6.64%, reaching $16.23 by May 06, 2026, with a range of $15.70 to $16.73. 1-Year Outlook: Projected gain of 259.26%, with price at $54.68 by February 05, 2027, within a range of $54.28 to $55.02.

Key Takeaways

Alto Neuroscience, Inc. (NYSE:ANRO) shares are flat -2.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alto Neuroscience, Inc. trading at a premium to the broader market with a P/E of -6.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $23.46, suggesting 54.14% upside. Our AI forecast model points to short-term weakness (-8.48% over two weeks), a medium-term rise (6.64% over three months), and a longer-term gain (259.26% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Alto Neuroscience, Inc. (ANRO) stock price?

Alto Neuroscience, Inc. (NYSE: ANRO) stock price is $15.22 in the last trading session. During the trading session, ANRO stock reached the peak price of $15.40 while $14.27 was the lowest point it dropped to. The percentage change in ANRO stock occurred in the recent session was 7.87% while the dollar amount for the price change in ANRO stock was $1.11.

ANRO's industry and sector of operation?

The NYSE listed ANRO is part of Biotechnology industry that operates in the broader Healthcare sector. Alto Neuroscience, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ANRO?

No Data

How ANRO did perform over past 52-week?

ANRO's closing price is 851.25% higher than its 52-week low of $1.60 where as its distance from 52-week high of $20.91 is -27.2%.

How many employees does ANRO have?

Number of ANRO employees currently stands at 76.

Link for ANRO official website?

Official Website of ANRO is: https://www.altoneuroscience.com

How do I contact ANRO?

ANRO could be contacted at phone 650 200 0412 and can also be accessed through its website. ANRO operates from 369 South San Antonio Road, Mountain View, CA 94022, United States.

How many shares of ANRO are traded daily?

ANRO stock volume for the day was 274.28K shares. The average number of ANRO shares traded daily for last 3 months was 322.84K.

What is the market cap of ANRO currently?

The market value of ANRO currently stands at $472.83M with its latest stock price at $15.22 and 31.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	76
Beta	2.85
Sales or Revenue	N/A
5Y Sales Change%	-1%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

ANRO Company Profile and Key Details

Alto Neuroscience

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook